Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
10.43
-0.28 (-2.61%)
Feb 21, 2025, 4:00 PM EST - Market closed
Evolent Health Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Evolent Health stock have an average target of 16.79, with a low estimate of 12 and a high estimate of 35. The average target predicts an increase of 60.98% from the current stock price of 10.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Evolent Health stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 6 | 6 |
| Buy | 5 | 6 | 6 | 6 | 6 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $17 → $16 | Buy | Reiterates | $17 → $16 | +53.40% | Feb 21, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +43.82% | Feb 21, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $12 | Buy | Reiterates | $12 | +15.05% | Feb 14, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +43.82% | Feb 12, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $15 → $13 | Buy | Maintains | $15 → $13 | +24.64% | Jan 28, 2025 |
Financial Forecast
Revenue This Year
2.59B
from 1.96B
Increased by 31.63%
Revenue Next Year
2.42B
from 2.59B
Decreased by -6.38%
EPS This Year
0.70
from -1.28
EPS Next Year
0.58
from 0.70
Decreased by -17.26%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.7B | 3.2B | 3.9B | |||
| Avg | 2.6B | 2.4B | 2.7B | |||
| Low | 2.5B | 2.0B | 2.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 37.6% | 24.4% | 59.5% | |||
| Avg | 31.6% | -6.4% | 13.3% | |||
| Low | 26.9% | -23.3% | -10.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.84 | 0.91 | 1.36 | ||
| Avg | 0.70 | 0.58 | 0.82 | ||
| Low | 0.60 | -0.04 | 0.18 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 31.3% | 135.9% | ||
| Avg | - | -17.3% | 42.6% | ||
| Low | - | - | -69.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.